A one-step sandwich enzyme immunoassay for tissue inhibitor of metalloproteinases-2
Related Experiment Videos
T Hayakawa1, N Fujimoto, J Zhang
1Department of Biochemistry, School of Dentistry, Aichi-Gakuin University, Nagoya, Japan.
Contributions to Nephrology
|January 1, 1994
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Shedding of membrane type 1 matrix metalloproteinase in a human breast carcinoma cell line.
Japanese journal of cancer research : Gann·1999
Characterization of a truncated recombinant form of human membrane type 3 matrix metalloproteinase.
European journal of biochemistry·1999
TIMP-2 promotes activation of progelatinase A by membrane-type 1 matrix metalloproteinase immobilized on agarose beads.
The Journal of biological chemistry·1998
Activation of the precursor of human stromelysin 2 and its interactions with other matrix metalloproteinases.
European journal of biochemistry·1998
Antimetastatic and antitumor effect of a recombinant human tissue inhibitor of metalloproteinases-2 in murine melanoma models.
Biological & pharmaceutical bulletin·1997
Unmet Clinical Needs and New Dialytic Approaches: Expanding the Therapeutic Horizon in Hemodialysis.
Contributions to nephrology·2026
Expanded Hemodialysis: Mechanisms and Equipment.
Contributions to nephrology·2026
Dialysis Membranes and Hemodialyzers.
Contributions to nephrology·2026
On-Line High-Volume Hemodiafiltration: Current Evidence and Clinical Outcomes.
Contributions to nephrology·2026
New Dialyzer Classification in Japan.
Contributions to nephrology·2026
Albumin-Leaking Membranes: Friends or Foes?
Contributions to nephrology·2026
Economic evaluation of PET-CT in staging and response assessment of patients with diffuse large B-cell lymphoma (DLBCL) in Thailand: a cost-utility analysis.
Cost effectiveness and resource allocation : C/E·2026
Serum Free Light Chains in Lymphoma: A Phenotype-First Framework for Biological Interpretation, Analytical Control, and Clinical Use.
Current oncology (Toronto, Ont.)·2026